“Unlike antibody-based vaccines, T-cell-based vaccines kill the infected cell, preventing virus replication, and could provide long-term memory to recipients,” he said.
Biovac CEO Dr Morena Makhoana said the collaboration was a strategic step in the quest to build vaccine-manufacturing capability in Africa.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: